Fluoxetine is the active medicine in Prozac, but the selected capsule label distinguishes four standalone indications from two uses with olanzapine. Its prolonged elimination also matters: interaction concerns can remain relevant after the last capsule. These FDA-labeled facts do not provide a personal stopping or switching plan.

If you are reading about an existing or proposed prescription, similar names and long warning sections can make the information hard to sort out. This article concerns one selected FDA record for Prozac oral capsules containing fluoxetine hydrochloride, not every formulation containing fluoxetine. It explains what the adult indications actually say, why combination treatment is a separate context, and how to interpret prolonged elimination, reactions, and interactions. It does not identify your dispensed strength, establish equivalence with another product, or give medication directions. Those limits matter even when the information accurately describes the selected product.

Which adult uses does this Prozac capsule label include?

The selected label includes four standalone adult uses, with different wording about treatment phases. Keeping the exact product in view, as explained in understanding medicine information, helps prevent broader assumptions. The accompanying Medication Guide's serious-risk information adds safety context rather than expanding those indications.

  • Major depressive disorder: acute and maintenance treatment.
  • Obsessive-compulsive disorder, or OCD: acute and maintenance treatment of obsessions and compulsions.
  • Moderate to severe bulimia nervosa: acute and maintenance treatment of binge-eating and vomiting behaviors.
  • Panic disorder, with or without agoraphobia: acute treatment.

Acute treatment addresses the condition during an active treatment phase; maintenance refers to ongoing treatment after an initial response. The distinction is part of the indication wording, not a timeline for your care. In particular, the selected indication for panic disorder does not use the same maintenance wording as the other three. See the FDA record, section 1.

The bulimia indication is especially specific. Naming binge-eating behaviors within bulimia nervosa does not establish an indication for binge-eating disorder, all eating difficulties, or weight management. The source here is Prozac application NDA018936, selected structured-label set c88f33ed-6dfb-4c5e-bc01-d8e36dd97299. Its effective_time value, 20260108, identifies the source record, not this article's publication date.

Why are fluoxetine alone and with olanzapine different?

Two depression indications in this label concern Prozac with olanzapine, not Prozac alone. That distinction belongs to product-specific prescribing information; understanding which serious-risk guide applies also matters because one medicine's information cannot stand in for the combination's full safety labeling.

The combination indications are acute depressive episodes associated with bipolar I disorder and the label's specified treatment-resistant depression context. For the latter, the label describes major depressive disorder that has not responded to two separate antidepressant trials of adequate dose and duration during the current episode. This is the product label's context, not a universal definition or treatment sequence. The FDA indication section explicitly excludes these two indications from Prozac monotherapy.

This comparison concerns indication wording only, not relative effectiveness, safety, or which treatment should come first.

Adult indications in the selected Prozac capsule label
Treatment contextRole stated in this labelBoundary
Major depressive disorderProzac alone: acute and maintenance treatmentDoes not establish an individual outcome
OCDProzac alone: acute and maintenance treatmentTargets obsessions and compulsions
Moderate to severe bulimia nervosaProzac alone: acute and maintenance treatmentSpecified binge-eating and vomiting behaviors
Panic disorderProzac alone: acute treatmentWith or without agoraphobia
Bipolar I depressive episodesProzac with olanzapine: acute treatmentNot a Prozac-alone indication
Label-defined treatment-resistant depressionProzac with olanzapineNot a Prozac-alone indication

The record directs professionals to additional combination-product labeling. This article does not summarize that separate label or provide a combination-treatment protocol.

Why does fluoxetine's long elimination matter for safety?

Fluoxetine and its major active metabolite, norfluoxetine, leave the body slowly. This makes the difference between general product information and personal directions important: a serious-risk statement about persistence cannot be converted into your own medication-change schedule.

A metabolite is a substance produced as the body processes a drug. Norfluoxetine remains active, so understanding exposure involves more than the original fluoxetine alone. The label explains that blood concentrations do not fully reflect a dose change immediately. It also identifies interaction concerns after fluoxetine has been discontinued. See FDA sections 5.14 and 7.7.

In practical terms, a last capsule is not necessarily the end of relevant exposure. A medicine introduced later may still encounter fluoxetine-related effects. That does not tell you when benefit begins, how long a particular symptom will last, or when a different medicine would be appropriate. Prolonged elimination is a safety consideration for professional treatment decisions, not a personal clearance estimate.

Which fluoxetine reactions are described in the label?

The label describes gastrointestinal, sleep-related, nervousness, sweating, tremor, and sexual-function findings, but their frequency differs across indications. The professional adverse-reaction section provides that context; serious-risk information should not be read as though every listed event is equally likely.

Reported trial findings include nausea, diarrhea, indigestion, and dry mouth. Sleep-related findings include insomnia and sleepiness, which are different experiences rather than one predictable response. Nervousness, anxiety, sweating, and tremor also appear. The indication-specific tables do not show identical patterns for depression, OCD, bulimia, and panic disorder. A pooled table combines groups and answers a different question from a table for one indication. See FDA section 6.1.

Sexual effects may involve desire, erection, ejaculation, or orgasm. The label notes that estimates can understate these experiences because they may go unreported. It also recognizes other possible causes, including the psychiatric condition itself. Separately, decreased appetite and significant weight loss are cautions, particularly for underweight people with depression or people with bulimia. They are not desirable treatment outcomes or evidence of a weight-management use. See FDA sections 5.6 and 5.17.

Controlled-trial observations and voluntary postmarketing reports are different evidence. Postmarketing reports come from a population of uncertain size, so they cannot reliably establish frequency or causation. Neither type predicts your experience or proves the cause of a new symptom. The label also cautions against comparing reaction rates across separate drugs' trials to rank safety.

Which serious fluoxetine warnings matter for adults?

Serious warnings need separate attention from common reactions. The role of Medication Guides in serious risks and the relationship between patient information and professional warnings help explain why a warning's importance is not simply a measure of how often it occurs.

The boxed warning includes young adults aged 18–24: short-term antidepressant studies found increased suicidal thoughts and behaviors in this age group. Those studies did not show the same increase in adults over 24. That difference does not mean older adults have no suicide risk. The warning calls for attention to worsening depression, suicidal thoughts, and unusual behavioral changes at every age. See the FDA boxed warning and section 5.1.

The warning about activation of mania or hypomania concerns unusual shifts in mood, energy, and behavior. These can include unusually elevated or irritable mood, markedly increased energy, much less sleep, or reckless behavior. Such changes warrant clinical attention rather than being assumed to mean that depression is improving. These examples explain the concern; they do not establish a diagnosis. See FDA section 5.4 on mania and hypomania.

Serotonin syndrome is a separate, potentially life-threatening reaction that can affect mental state, body-temperature regulation, and muscle function. It can occur with fluoxetine alone, and other serotonergic medicines increase the risk. It is not another name for ordinary nervousness or a way to explain every new symptom. See FDA section 5.2 on serotonin syndrome.

Severe allergic reactions can involve swelling or breathing difficulty. Increased bleeding, low blood sodium, seizures, and angle-closure glaucoma in susceptible people are distinct concerns. Low sodium can affect thinking and steadiness; the eye warning concerns a particular anatomical susceptibility, not every type of glaucoma. QT prolongation concerns the heart's electrical timing and can be associated with dangerous rhythms. These are separate risks, not a checklist for diagnosing yourself. See FDA sections 5.3 and 5.5–5.11.

Suspected serious reactions require prompt medical attention rather than interpretation through this article. For immediate danger or a life-threatening reaction, call 911. For suicide or crisis support, call or text 988. Do not delay urgent help while seeking routine outpatient information. NIMH provides crisis and emergency guidance.

Why do interactions extend beyond antidepressants?

Fluoxetine interactions involve several mechanisms and medicines used outside depression care. Reading the exact product's interaction information, alongside its patient-directed serious-risk information, is more useful than assuming that only another antidepressant could matter.

Fluoxetine strongly inhibits CYP2D6, an enzyme pathway involved in processing certain medicines. This can increase exposure to some other drugs. The label names certain antidepressants, antipsychotics, and heart-rhythm medicines among the relevant categories. This is distinct from interactions caused by overlapping effects on serotonin, bleeding, or cardiac electrical timing. The FDA interaction sections describe these different concerns.

  • CYP2D6-related effects: certain medicines, including flecainide and propafenone, can be affected by inhibited drug processing.
  • Serotonergic combinations: examples such as tramadol, triptans, lithium, buspirone, and St. John's wort raise serotonin-syndrome concerns.
  • Bleeding-related combinations: aspirin, NSAIDs, and warfarin can add to bleeding risk.
  • QT-related combinations: some antipsychotics, antibiotics, and heart-rhythm medicines can add cardiac concerns. Pimozide and thioridazine are specifically contraindicated combinations in this label.

These examples are not a complete interaction checker or a list of acceptable alternatives. An over-the-counter product can matter, and an absent name does not establish compatibility. Because fluoxetine-related exposure can persist, interaction review may involve recent medication history as well as medicines taken together today. No timing interval or combination decision can be inferred from this summary.

What can this label establish about personal benefit?

The label establishes product-specific indications and safety information, not a forecast of your response. That is a central limit of general medicine information and of Medication Guide risk statements: neither tells you exactly what benefit or unwanted effect you will experience.

Prozac is classified as a selective serotonin reuptake inhibitor, or SSRI. The label says its exact therapeutic mechanism is unknown and is presumed to relate to inhibition of serotonin uptake by nerve cells. That does not establish that depression demonstrates a serotonin deficiency. See FDA section 12.1.

The supplied extract does not contain the full Clinical Studies section, so it does not support a detailed account of effectiveness studies or comparative benefit. More broadly, an approved indication is not a guarantee. NIMH describes treatment planning as depending on individual needs and medical circumstances under professional guidance. This article explains the selected label without diagnosing, prescribing, or directing a medication change.

Written by Tim Francis, SUD Content Specialist.

Frequently asked questions

Are Prozac and fluoxetine different names for the same thing?

Prozac is the brand name in the selected record; its oral capsules contain fluoxetine hydrochloride. That identifies the product discussed here, but it does not identify the strength or manufacturer of your prescription. This article does not establish equivalence between your dispensed product and another formulation or package.

Does the panic-disorder indication mean all anxiety uses are approved?

No. The selected capsule label specifies acute treatment of panic disorder, with or without agoraphobia. That wording does not establish approved treatment for every anxiety condition, including generalized anxiety disorder or PTSD. It also cannot determine whether an individual's prescription is appropriate; that is a different question from identifying the label's indications.

Does the bulimia indication also cover binge-eating disorder?

No. In this label, binge-eating and vomiting behaviors are specified within moderate to severe bulimia nervosa. Naming those behaviors does not create an indication for binge-eating disorder or all disordered eating. Decreased appetite and weight loss also appear as cautions, not as evidence of an approved weight-management purpose.

Can fluoxetine interactions still matter after the last capsule?

Yes. The label identifies prolonged elimination of fluoxetine and its active metabolite, norfluoxetine, and explains that interaction relevance can persist after discontinuation. This does not provide a personal estimate of clearance or a safe interval for another medicine. Medication timing and changes require product-specific professional judgment, not a general article.

Does a listed reaction prove fluoxetine caused my symptom?

No. A listed reaction provides relevant product information, but it does not establish the cause of an individual's symptom. Trial observations have specific study conditions, while voluntary postmarketing reports cannot reliably establish frequency or causation. Serious or urgent symptoms still need timely medical attention even when their cause is uncertain.

Fluoxetine: Related Guides

For more context, explore the full article library, Asenapine: Labeled Uses and Safety for Adults | PHP/IOP MA, Citalopram: Labeled Uses and Safety for Adults | PHP/IOP MA.